



NEWS RELEASE

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026

2026-10-08

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that Lantern management will be presenting at the ThinkEquity Conference on Thursday, October 15, 2026, at 3:30 p.m. ET at the Mandarin Oriental in New York, NY.

- Webcast Link:
<https://event.summitcast.com/view/GXv6JAoMEphytK6ggozCk7/VS4pGMrvkqg2xwHrNQevWX>
- Conference Registration Link: https://www.meetmax.com/sched/event_138793/conference_register.html

Lantern Pharma management will be available for one-on-one meetings held throughout the conference.

About Lantern Pharma

Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage, AI-driven precision oncology company developing targeted therapies for high-need cancer indications. The Company's proprietary RADR® AI platform integrates multi-omic biomarker data with clinical outcomes to identify patient subgroups most likely to respond to specific therapies, enabling more efficient clinical development and biomarker-driven trial design. Lantern's pipeline includes LP-300 (HARMONIC™ trial in never-smoker NSCLC), LP-184, and LP-284, with additional preclinical programs identified

through RADR®.

For more information, visit:

- Website: **www.lanternpharma.com**
- LinkedIn: **<https://www.linkedin.com/company/lanternpharma/>**
- X: @lanternpharma

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® and Open-Medicine AI platforms in identifying drug candidates, accelerating drug development, and generating revenue through software licensing and subscription models; our strategic plans to advance the development of our drug candidates; the planned commercialization of our AI platforms, including Open-Medicine AI; estimates regarding the development timing for our drug candidates and AI platforms; our research and development efforts of our internal drug discovery programs and the utilization of our AI platforms to streamline the drug development process; estimates regarding patient populations, potential markets and potential market sizes; and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others.

Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned development programs and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that our Open-Medicine AI commercialization efforts may not generate the anticipated revenue or achieve the expected market adoption, (v) the risk that no drug product based on our proprietary AI platforms has received FDA marketing approval or otherwise been incorporated into a commercial product, (vi) the risk that ongoing partnership and collaborations discussions may not result in definitive agreements on acceptable terms or at all, (vii) market and other conditions, and (viii) technical, scientific, regulatory, financial, competitive, and operational risks and those other factors set

forth in the Risk Factors sections in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 30, 2026.

You may access our Annual Report on Form 10-K for the year ended December 31, 2025 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

Investor Contact

Investor Relations

ir@lanternpharma.com

+1-972-277-1136

Source: Lantern Pharma Inc.